We are live on ! Find out more
SVA

Sinovac Biotech, Ltd

Delisted

SVA was delisted on the 22nd of February, 2019.

36 hedge funds and large institutions have $66.9M invested in Sinovac Biotech, Ltd in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 13

3% less funds holding

Funds holding: 3736 (-1)

5% less capital invested

Capital invested by funds: $70.8M → $66.9M (-$3.86M)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

Holders
36
Holders Change
-1
Holders Change %
-2.7%
% of All Funds
0.96%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
12
Reduced
13
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$31.7M +$791K +134,447 +3%
O
2
OrbiMed
New York
$15.7M
Renaissance Technologies
3
Renaissance Technologies
New York
$8.7M +$464K +78,900 +6%
USAA
4
United Services Automobile Association
Texas
$2.04M -$72.7K -12,363 -3%
FIM
5
Freedom Investment Management
Connecticut
$1.31M -$39.6K -6,739 -3%
ACP
6
Acuta Capital Partners
California
$1.21M +$423K +71,855 +54%
Invesco
7
Invesco
Georgia
$673K +$253 +43 +0%
Citigroup
8
Citigroup
New York
$644K -$1.03M -174,307 -61%
PRCM
9
Pine River Capital Management
Minnesota
$627K -$2.6M -441,701 -81%
Two Sigma Investments
10
Two Sigma Investments
New York
$539K +$202K +34,307 +60%
CS
11
Credit Suisse
Switzerland
$527K +$171K +29,085 +48%
Deutsche Bank
12
Deutsche Bank
Germany
$491K -$5.76K -980 -1%
California Public Employees Retirement System
13
California Public Employees Retirement System
California
$382K -$27.1K -4,600 -7%
GP
14
GLG Partners
United Kingdom
$341K
Morgan Stanley
15
Morgan Stanley
New York
$291K -$5.76K -979 -2%
PAM
16
Panagora Asset Management
Massachusetts
$250K -$2.82K -479 -1%
State Street
17
State Street
Massachusetts
$216K +$116K +19,806 +117%
OAC
18
OMERS Administration Corp
Ontario, Canada
$211K
Two Sigma Advisers
19
Two Sigma Advisers
New York
$199K -$40K -6,800 -17%
VAM
20
Verity Asset Management
North Carolina
$175K +$175K +29,726 New
GC
21
Guggenheim Capital
Illinois
$146K +$218 +37 +0.1%
Geode Capital Management
22
Geode Capital Management
Massachusetts
$137K +$929 +158 +0.7%
TC
23
TFS Capital
Pennsylvania
$93K -$52.7K -8,967 -36%
Citadel Advisors
24
Citadel Advisors
Florida
$77K +$77K +13,084 New
GBBWRPM
25
Genovese Burford & Brothers Wealth & Retirement Plan Management
California
$58K

SVA Hedge Fund Activity: Q3 2016 in Review

36 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q3 2016, worth a combined $66.9M — down 5.5% from $70.8M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of SVA and 3 opened new positions — a net loss of 1 holder — while 13 trimmed existing stakes and 12 added.

The largest buyer was Wellington Management Group, adding an estimated $791K. The largest seller was Pine River Capital Management, cutting an estimated $2.6M.

  • 36 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q3 2016, down from 37 in Q2 2016.
  • Funds reported $66.9M of Sinovac Biotech, Ltd stock for Q3 2016, down 5.5% quarter-over-quarter.
  • 3 funds opened new Sinovac Biotech, Ltd positions in Q3 2016 and 4 closed out, a net change of -1 holder.
  • The largest Sinovac Biotech, Ltd buyer in Q3 2016 was Wellington Management Group, an estimated $791K added.
  • The largest Sinovac Biotech, Ltd seller in Q3 2016 was Pine River Capital Management, an estimated $2.6M sold.

Based on aggregated 13F filings for Q3 2016.